- Home
- MGRX vs ALLR Comparison
MGRX vs ALLR Comparison
Compare MGRX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- ALLR
- Stock Information
- Founded
- MGRX 2021
- ALLR 2004
- Country
- MGRX United States
- ALLR United States
- Employees
- MGRX N/A
- ALLR N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- ALLR Health Care
- Exchange
- MGRX Nasdaq
- ALLR Nasdaq
- Market Cap
- MGRX 25.2M
- ALLR 20.2M
- IPO Year
- MGRX 2023
- ALLR N/A
- Fundamental
- Price
- MGRX $1.76
- ALLR $1.31
- Analyst Decision
- MGRX
- ALLR Strong Buy
- Analyst Count
- MGRX 0
- ALLR 1
- Target Price
- MGRX N/A
- ALLR $9.25
- AVG Volume (30 Days)
- MGRX 288.0K
- ALLR 287.7K
- Earning Date
- MGRX 11-14-2025
- ALLR 11-14-2025
- Dividend Yield
- MGRX N/A
- ALLR N/A
- EPS Growth
- MGRX N/A
- ALLR N/A
- EPS
- MGRX N/A
- ALLR N/A
- Revenue
- MGRX $516,030.00
- ALLR N/A
- Revenue This Year
- MGRX N/A
- ALLR N/A
- Revenue Next Year
- MGRX N/A
- ALLR N/A
- P/E Ratio
- MGRX N/A
- ALLR N/A
- Revenue Growth
- MGRX N/A
- ALLR N/A
- 52 Week Low
- MGRX $1.32
- ALLR $0.61
- 52 Week High
- MGRX $6.15
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- MGRX 39.17
- ALLR 40.55
- Support Level
- MGRX $1.83
- ALLR $1.34
- Resistance Level
- MGRX $2.28
- ALLR $1.45
- Average True Range (ATR)
- MGRX 0.23
- ALLR 0.08
- MACD
- MGRX -0.07
- ALLR -0.01
- Stochastic Oscillator
- MGRX 4.35
- ALLR 0.00
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.